Media stories about Mednax (NYSE:MD) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mednax earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.3877954342982 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- MEDNAX (MD) Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Mednax tops Street 3Q forecasts (finance.yahoo.com)
- With A Recent ROE Of 10.86%, Can MEDNAX Inc (MD) Catch Up To Its Industry? (finance.yahoo.com)
- Edited Transcript of MD earnings conference call or presentation 1-Nov-17 2:00pm GMT (finance.yahoo.com)
- KeyCorp Analysts Give Mednax, Inc (MD) a $51.00 Price Target (americanbankingnews.com)
Mednax (NYSE:MD) last posted its earnings results on Wednesday, October 25th. The company reported $0.87 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.87. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same period in the previous year, the business earned $1.09 EPS. The business’s quarterly revenue was up 4.9% on a year-over-year basis.
A number of equities research analysts have commented on MD shares. Jefferies Group LLC reiterated a “hold” rating and issued a $53.00 price target (up from $50.00) on shares of Mednax in a research note on Thursday, July 6th. BidaskClub cut Mednax from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Mizuho reiterated a “neutral” rating and issued a $48.00 price target (down from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. Robert W. Baird reiterated a “hold” rating and issued a $47.00 price target on shares of Mednax in a research note on Sunday, September 3rd. Finally, KeyCorp upgraded Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price target for the company in a research note on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company’s stock. Mednax presently has an average rating of “Hold” and an average price target of $55.44.
TRADEMARK VIOLATION NOTICE: “Mednax (MD) Receiving Somewhat Favorable Press Coverage, Report Finds” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2017/11/02/mednax-md-receiving-somewhat-favorable-press-coverage-report-finds.html.
In other Mednax news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is owned by corporate insiders.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
What are top analysts saying about Mednax Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mednax Inc and related companies.